Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.38 |
| ▸ | PNMT | P11086 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
| ▸ | WNT3A | P56704 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26100663 | 0.98 | MPO (0.43) | MPOADORA2APNMTDRD2DRD1 | |
| SCHEMBL34462978 | 0.86 | MPO (0.43) | MPOADORA2ADRD2DRD1AKT1 | |
| SCHEMBL34463082 | 0.86 | MPO (0.43) | MPOADORA2ADRD2DRD1AKT1 | |
| SCHEMBL7274441 | 0.83 | MPO (0.42) | MPOADORA2ADRD2DRD1AKT1 | |
| SCHEMBL23719269 | 0.82 | PNMT (0.33) | MPOADORA2APNMT | |
| SCHEMBL7651499 | 0.81 | MPO (0.41) | MPOADORA2ADRD2DRD1AKT1 | |
| SCHEMBL2663368 | 0.81 | MPO (0.41) | MPOADORA2ADRD2DRD1AKT1 | |
| SCHEMBL25844897 | 0.81 | MPO (0.41) | MPOADORA2ADRD2DRD1AKT1 | |
| SCHEMBL23719256 | 0.80 | MPO (0.32) | MPOPNMT | |
| SCHEMBL5330644 | 0.79 | MPO (0.40) | MPOADORA2ADRD2DRD1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428413-B2 | Rho kinase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20220388998-A1 | RHO KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2022-12-08 | — | — | US | disclosed |
| EP-3939974-A1 | MODULATORS OF ROR-GAMMA | Vitae Pharmaceuticals, LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3408268-B1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210094940-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2021-04-01 | — | — | US | disclosed |
| US-20210094940-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2021-04-01 | — | — | US | disclosed |
| US-10829481-B2 | Benzimidazole derivatives as modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829481-B2 | Benzimidazole derivatives as modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190352286-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2019-11-21 | — | — | US | disclosed |
| US-20190352286-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2019-11-21 | — | — | US | disclosed |
| WO-2017132432-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| WO-2017132432-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| US-8546374-B2 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-12-27 | — | — | US | disclosed |
| US-8217067-B2 | Antiinflammatory agents, antidepressants, analgesics, purinergic receptor antagonists; neurodegenerative diseases, spinal cord injuries; 1-(2,3-dichlorophenyl)-N-[(2-methylphenyl)methyl]-1H-tetraazol-5-amine | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| US-7723367-B2 | Amino-tetrazoles analogues and methods of use | ABBOTT LABORATORIES (US) | 2010-05-25 | — | — | US | disclosed |
| US-7704997-B1 | Amino-tetrazole analogues and methods of use | ABBOTT LABORATORIES (US) | 2010-04-27 | — | — | US | disclosed |
| US-20080171733-A1 | Amino-Tetrazoles Analogues and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-17 | — | — | US | disclosed |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428413-B2 | Rho kinase inhibitors and compositions and methods of use thereof | ROCK1, ROCK2, RHOA | MPO 1800/4885ADORA2A 2749/4885PNMT 1682/4885 |
| US-20190352286-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | MPO 2851/4885ADORA2A 2796/4885PNMT 4448/4885 |
| US-10829481-B2 | Benzimidazole derivatives as modulators of ROR-gamma | RORB, RORC, RORA | MPO 2650/4885ADORA2A 2255/4885PNMT 4473/4885 |
| US-20080171733-A1 | Amino-Tetrazoles Analogues and Methods of Use | P2RX7, P2RX2, P2RX5 | MPO 1946/4885ADORA2A 16/4885PNMT 1293/4885 |
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | P2RX7, P2RX2, P2RX5 | MPO 1946/4885ADORA2A 16/4885PNMT 1293/4885 |
| US-20220388998-A1 | RHO KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | ROCK1, ROCK2, RHOA | MPO 1800/4885ADORA2A 2749/4885PNMT 1682/4885 |
| US-20210094940-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | MPO 1706/4885ADORA2A 1660/4885PNMT 4617/4885 |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | P2RX7, P2RX2, P2RX5 | MPO 1946/4885ADORA2A 16/4885PNMT 1293/4885 |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | P2RX7, P2RX2, P2RX3 | MPO 1851/4885ADORA2A 16/4885PNMT 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.